The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study
Open accessAbstract
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While similar in distribution, the magnitude of the CBF response in depression patients was distinctly less than that in the study of healthy volunteers by Riba et al. [141].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“Parametric mapping of CBF changes indicated increases in some very small clusters (<50 voxels) localized to the left nucleus accumbens, right insula, and left cingulate cortex, which the authors felt to be regions activated by antidepressant treatments.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“the mean Hamilton depression rating scales declined from 25 to 15 in the three hours after administration, and remained around 10 during the following three weeks.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“These open label [22–24] and randomised control [21] trials have suggested that ayahuasca may produce rapid and significant reductions in depression symptoms in as little as 1 day.”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [23]
In the citing paper
“Several studies, including one RCT, have highlighted a similar rapid onset and sustained antidepressant effect after a single ingestion in patients diagnosed with treatment-resistant depression (3, 36).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [36]
In the citing paper
“Similarly, ayahuasca's anti-depressive potential has been demonstrated in pilot studies and replicated in a RCT on patients with treatment-resistant depression (33, 36, 63).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
In the citing paper
“Most of these studies however suffer from low methodological validity and are mostly open-label, yet they have yielded preliminary evidence for the capacity of psychedelic substances for treating addiction, depression, anxiety, and eating disorders (29–35).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
In the citing paper
“For example, enhanced activation of the ACC and other prefrontal regions was observed in novice and experienced meditators (120–122), and as a result of ayahuasca administration (33, 63).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
Citations
Cites
Pizzagalli, D. A., Holmes, A. J., Dillon, D. G., Goetz, E. L., Birk, J. L., Bogdan, R., Dougherty, D. D., Iosifescu, D. V., Rauch, S. L., & Fava, M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081201 · Cited by 1,232
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
The subgenual anterior cingulate cortex in mood disorders
Drevets, W. C., Savitz, J., & Trimble, M. (2008) · CNS Spectrums · doi:10.1017/s1092852900013754 · Cited by 1,109
A meta‐analytic study of changes in brain activation in depression
Fitzgerald, P. B., Laird, A. R., Maller, J., & Daskalakis, Z. J. (2008) · Human Brain Mapping · doi:10.1002/hbm.20426 · Cited by 903
Bewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Self-citationPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Self-citationVollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Research works printed but not linked: 1
- Moreno, 1998, Hamilton (HAM-D) Montgomery Asberg (MADRS) depression rating scales., Rev Psiquiatr Clin, 25, 262
Cited by
Sorted by citations
Items 101–200 of 466
Berlowitz, I., Walt, H., Ghasarian, C., Mendive, F., & Martin-Soelch, C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1607956 · Cited by 72
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Zeifman, R. J., & Wagner, A. C. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.001 · Cited by 67
Giluk (2009) · doi:10.1017/s003329172000389x · Cited by 68
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 73
SANTOS, R. G. D., & Hallak, J. E. C. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1260189 · Cited by 66
Self-citationOn the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
Zeifman, R. J., Singhal, N., Breslow, L., & Weissman, C. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00024 · Cited by 66
Rosenblat, J. D., Husain, M. I., Lee, Y. L., McIntyre, R. S., Mansur, R. B., Castle, D. J., Offman, H., Parikh, S. V., Frey, B. N., Schaffer, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221111371 · Cited by 68
Argento, E., Strathdee, S. A., Tupper, K. W., Braschel, M. C., Wood, E., & Shannon, K. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016025 · Cited by 63
Pharmacokinetics of N,N-dimethyltryptamine in Humans
Good, M., Joel, Z., Benway, T. A., Routledge, C. A., Timmermann, C., Erritzøe, D., Weaver, R., Allen, G., Hughes, C., Topping, H., et al. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00822-y · Cited by 71
SANTOS, R. G. D., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. C. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s300656 · Cited by 73
Self-citationPsychological variables implied in the therapeutic effect of ayahuasca: A contextual approach
Franquesa, A., Sainz-Cort, A., Gandy, S., Soler, J., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.04.012 · Cited by 58
Modulatory effects of ayahuasca on personality structure in a traditional framework
Netzband, N., Ruffell, S., Linton, S., Tsang, W., & Wolff, T. J. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05601-0 · Cited by 56
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Pic-Taylor, A., Mortari, M. R., & Caldas, E. D. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00547-w · Cited by 58
Herbal Highs: Review on Psychoactive Effects and Neuropharmacology
Graziano, S., Orsolini, L., Rotolo, M. C., Tittarelli, R., Schifano, F., & Pichini, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666161031144427 · Cited by 60
Luoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
Evens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
SANTOS, R. G. D., & Hallak, J. E. C. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.053 · Cited by 66
Self-citationdos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
Self-citationPsychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
Lowe, H. I. C., Toyang, N. J., Steele, B., Grant, J., Ali, A., Gordon, L., & Ngwa, W. F. (2022) · Molecules · doi:10.3390/molecules27082520 · Cited by 58
Riga, M. S., Lladó-Pelfort, L., Artigas, F., & Celada, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.049 · Cited by 50
Pre-clinical investigations of β-carboline alkaloids as antidepressant agents: A systematic review
Ferraz, C. A. A., Júnior, R. G. D. O., Picot, L., Almeida, J. R. G. D. S., & Nunes, X. P. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.104196 · Cited by 56
Husain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1076459 · Cited by 50
Whelan, A., & Johnson, M. I. (2018) · Pain Management · doi:10.2217/pmt-2017-0068 · Cited by 51
Yaden, D. B., Berghella, A. P., Regier, P. S., Garcia‐Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103380 · Cited by 55
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 61
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches
Duarte, P., Cuadrado, A., & Leon, R. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_384 · Cited by 49
Rocha, J. M., Rossi, G. N., Osório, F. D. L., Bouso, J. C., Silveira, G. D. O., Yonamine, M., Campos, A. C., Bertozi, G., Hallak, J. E. C., & SANTOS, R. G. D. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001396 · Cited by 50
Self-citationBrennan, B., Kelman, A. R., & Belser, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0007 · Cited by 50
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02091-6 · Cited by 52
Schindler, E. A. D., Wallace, R. M., Sloshower, J., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 51
Ayahuasca’s Antidepressant Effects Covary with Behavioral Activation as Well as Mindfulness
Mian, M. N., Altman, B. R., & Earleywine, M. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1674428 · Cited by 47
Rodrigues, L. S., Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01267-7 · Cited by 47
Self-citationAyahuasca's therapeutic potential: What we know – and what not
Maia, L. O., Daldegan‐Bueno, D., Wießner, I., de Araújo, D. B., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.008 · Cited by 54
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 52
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. X.-Y. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 45
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43
Kelley, D. P., Venable, K., Destouni, A., Billac, G., Ebenezer, P., Stadler, K., Nichols, C., Barker, S., & Francis, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00660 · Cited by 42
Potential use of ayahuasca in grief therapy
González, D., Carvalho, M., Cantillo, J., Aixalá, M., & Farré, M. (2019) · OMEGA - Journal of Death and Dying · doi:10.1177/0030222817710879 · Cited by 44
Rocha, J. M., Osório, F. D. L., Crippa, J. A. S., Bouso, J. C., Rossi, G. N., Hallak, J. E. C., & SANTOS, R. G. D. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319845774 · Cited by 43
Self-citationSouza, R. C. Z., Zandonadi, F. D. S., Freitas, D. P., Tófoli, L. F., & Sussulini, A. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.06.014 · Cited by 43
Effects of DMT on mental health outcomes in healthy volunteers
Timmermann, C., Zeifman, R. J., Erritzøe, D., Nutt, D., & Carhart-Harris, R. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-53363-y · Cited by 48
The Shipibo ceremonial use of ayahuasca to promote well-being: An observational study
Gonzalez, D., Cantillo, J., Perez, I., Carvalho, M., Aronovich, A., Farre, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623923 · Cited by 40
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 50
Koslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 42
Villiger, D., & Trachsel, M. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108816 · Cited by 43
Gonçalves, J., Luís, Â., Gallardo, E., & Duarte, A. P. (2021) · Molecules · doi:10.3390/molecules26051397 · Cited by 45
Eleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39
“For example, enhanced activation of the ACC and other prefrontal regions was observed in novice and experienced meditators (120–122), and as a result of ayahuasca administration (33, 63).”
BackgroundPsychedelic treatment of functional neurological disorder: a systematic review
Butler, M., Seynaeve, M., Nicholson, T. R., Pick, S., Kanaan, R., Lees, A. J., Young, A. H., & Rucker, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320912125 · Cited by 39
Role of psilocybin in the treatment of depression
Mahapatra, A., & Gupta, R. G. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316676092 · Cited by 42
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.002 · Cited by 38
Rocha, J. M., Rossi, G. N., Osório, F. D. L., Bouso, J. C., Silveira, G. D. O., Yonamine, M., Crevelin, E. J., Queiroz, M. E. C., Hallak, J. E. C., & SANTOS, R. G. D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.688439 · Cited by 36
Self-citationLong-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
SANTOS, R. G. D., Sanches, R. F., Osório, F. D. L., & Hallak, J. E. C. (2018) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000149 · Cited by 37
Self-citationArgento, E., Braschel, M. C., Walsh, Z., Socias, M. E., & Shannon, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798610 · Cited by 38
Psychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 37
Nootropic effects of LSD: Behavioral, molecular and computational evidence
Ornelas, I. M., da Silva, F. A. C., Wießner, I., Marcos, E., de Araújo, D. B., Goto‐Silva, L., Nascimento, J. M., Silva, S. R. B., Costa, M., Falchi-Carvalho, M., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114148 · Cited by 37
Psilocybin and Other Classic Psychedelics in Depression
Nutt, D., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 39
Egger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 37
A Qualitative Study of Intention and Impact of Ayahuasca Use by Westerners
Bathje, G. J., Fenton, J., Pillersdorf, D., & Hill, L. C. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211008331 · Cited by 34
Ayahuasca, a psychedelic beverage, modulates neuroplasticity induced by ethanol in mice
Almeida, C. A. D. F., Pereira-Júnior, A. A., Rangel, J. G., Pereira, B. P., Costa, K. C. M., Bruno, V., Silveira, G. D. O., Ceron, C. S., Yonamine, M., Camarini, R., et al. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113546 · Cited by 35
Psychedelics in the treatment of unipolar and bipolar depression
Bosch, O. G., Halm, S., & Seifritz, E. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00265-5 · Cited by 38
Aicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33
Rossi, G. N., Guerra, L. T. L., Baker, G. B., Dursun, S. M., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2022) · Biomolecules · doi:10.3390/biom12111618 · Cited by 33
Self-citationA Public-Health-Based Vision for the Management and Regulation of Psychedelics
Haden, M., Emerson, B., & Tupper, K. W. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1202459 · Cited by 39
Dornbierer, D. A., Marten, L., Mueller, J., Aicher, H. D., Mueller, M. J., Boxler, M., Kometer, M., Kosanic, D., von Rotz, R., Puchkov, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1246892 · Cited by 32
The role of serotonin neurotransmission in rapid antidepressant actions
Pehrson, A. L., Roberts, D., Khawaja, A., & McNair, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06098-5 · Cited by 35
Marcus, O. (2022) · Interdisciplinary Science Reviews · doi:10.1080/03080188.2022.2075201 · Cited by 32
Andrade, T. S., Oliveira, R., da Silva, M. L., von Zuben, M. V., Grisólia, C. K., Domingues, I., Caldas, E. D., & Pic‐Taylor, A. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.08.001 · Cited by 32
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32
The renaissance in psychedelic research: What do preclinical models have to offer
Murnane, K. S. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.003 · Cited by 35
New insights into the chemical composition of Ayahuasca
Rodríguez, L., López, A., Moyna, G., Seoane, G. A., Davyt, D., Vázquez, Á., Hernández, G., & Carrera, I. (2022) · ACS Omega · doi:10.1021/acsomega.2c00795 · Cited by 30
Więckiewicz, G., Stokłosa, I., Piegza, M. J., Gorczyca, P. W., & Pudło, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080793 · Cited by 34
Falchi-Carvalho, M., Wießner, I., Silva, S. R. B., Maia, L. O., Barros, H., Laborde, S., Arichelle, F., Tullman, S., Silva-Costa, N., Assunção, A., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.12.006 · Cited by 31
Dimethyltryptamine: Endogenous Role and Therapeutic Potential
Rodrigues, A. V., Almeida, F., & Vieira‐Coelho, M. A. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1602291 · Cited by 34
Efficacité des psychédéliques en psychiatrie, une revue systématique
Berkovitch, L., Roméo, B., Karila, L., Gaillard, R., & Benyamina, A. (2021) · L Encéphale · doi:10.1016/j.encep.2020.12.002 · Cited by 35
Stress, memory, and implications for major depression
de Sousa, G. M., Vargas, H. D. Q., Barbosa, F. F., & Coelho, N. L. G. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113410 · Cited by 32
Bioactive Azepine-Indole Alkaloids from Psychotria nemorosa
Klein‐Júnior, L. C., Cretton, S., Heyden, Y. V., de Gasper, A. L., Ebrahimi, S. N., Christen, P., & Henriques, A. T. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00469 · Cited by 29
History repeating: A roadmap to address common problems in psychedelic sciencePreprint
van Elk, M., & Fried, E. I. (2023) · doi:10.31234/osf.io/ak6gx · Cited by 30
Maternal and developmental toxicity of the hallucinogenic plant-based beverage ayahuasca in rats
da Motta, L. G., de Morais, J. A., Tavares, A. C. A. M., Vianna, L. M. D. S., Mortari, M. R., de Amorim, R. F. B., de Carvalho, R. R., Paumgartten, F. J. R., Pic‐Taylor, A., & Caldas, E. D. (2018) · Reproductive Toxicology · doi:10.1016/j.reprotox.2018.03.002 · Cited by 28
Rush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Loewinger, G. C., Spitalier, A., & Mendive, F. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659644 · Cited by 32
Perkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 33
Boehnke, K. F., Cox, K., Weston, C. L., Herberholz, M., Glynos, N. G., Kolbman, N., Fields, C. W., Barron, J., & Kruger, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1224551 · Cited by 30
Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?
Malcolm, B., & Lee, K. C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.01.039 · Cited by 34
How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy
Orsolini, L., Chiappini, S., Papanti, D., Latini, R., Volpe, U., Fornaro, M., Tomasetti, C., Vellante, F., & Berardis, D. D. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2728 · Cited by 33
Thal, S. B., Baker, P., Marinis, J., Wieberneit, M., Sharbanee, J. M., Bruno, R., Skeffington, P., & Bright, S. J. (2023) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2945 · Cited by 32
Ayahuasca Beverages: Phytochemical Analysis and Biological Properties
Gonçalves, J., Luís, Â., Gradillas, A., Garcı́a, A., Restolho, J., Fernández, N., Domingues, F., Gallardo, E., & Duarte, A. P. (2020) · Antibiotics · doi:10.3390/antibiotics9110731 · Cited by 29
Ayahuasca for the Treatment of Depression
Palhano-Fontes, F., Soares, B. L., Coelho, N. L. G., Arcoverde, E., & de Araújo, D. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_277 · Cited by 26
Kaup, K., Vasser, M., Tulver, K., Munk, M., Pikamäe, J., & Aru, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1088896 · Cited by 31
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V., Ramaekers, J. G., & Mason, N. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.883869 · Cited by 26
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 31
Tófoli, L. F., & de Araújo, D. B. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.06.005 · Cited by 35
Kohek, M., Ona, G., van Elk, M., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2077155 · Cited by 24
Self-citation(2024) · doi:10.1177/02698811231215420 · Cited by 25
Beyond serotonin: newer antidepressants in the future
Rakesh, G., Pae, C., & Masand, P. S. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341310 · Cited by 26
Acute Psychological Adverse Reactions in First-Time Ritual Ayahuasca Users
Gómez-Sousa, M. D. L., Jiménez-Garrido, D. F., Oña, G., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Bouso, J. C. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001343 · Cited by 26
Self-citationVilliger, D. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357669 · Cited by 27
Eckernäs, E., Timmermann, C., Carhart-Harris, R. L., Röshammar, D., & Ashton, M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13410 · Cited by 25
Psychedelics and mindfulness: A systematic review and meta-analysis
Radakovic, C., Radaković, R., Peryer, G., & Geere, J. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00218 · Cited by 31
Ahmadi, J., & Jahromi, M. S. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.211765 · Cited by 24
Politi, M., Tresca, G., Menghini, L., & Ferrante, C. (2021) · Planta Medica · doi:10.1055/a-1675-3840 · Cited by 25
Metadata
- Authors
- Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Corresponding author
- Sanches, Rafael Faria
- Macedo, Ligia R.H.
- Crippa, José Alexandre S.
- Hallak, Jaime E.C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2016-02
- Volume
- 36
- Issue
- 1
- Pages
- 77-81
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2419844652
- Cited by
- 466
- References
- 26
- Citations by year
- 2026: 31 · 2025: 34 · 2024: 63 · 2023: 55 · 2022: 68 · 2021: 59 · 2020: 39 · 2019: 28 · 2018: 41 · 2017: 31 · 2016: 14
- FWCI
- 35.96
- Type
- journal article
- Language
- en
- Open access
- green
- repositorio.ufrn.br
- Licence
- other-oa
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ayahuasca, recurrent depression, antidepressant effects, dimethyltryptamine, harmine, 5-HT2A receptor agonism, monoamine oxidase A inhibition, regional cerebral blood flow, nucleus accumbens, insula, dissociative states, adverse effects, single-dose administration
- MeSH terms
- Administration, Oral, Adult, Antidepressive Agents, Brain, Major Depressive Disorder, Female, Hallucinogens, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Time Factors, Tomography, Emission-Computed, Single-Photon, Treatment Outcome, Plant Preparations, Banisteriopsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
